Fidelity Investments’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Fidelity Investments’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-535,772	Closed	-$12.7M	–	4481
2019 Q3	$12.7M	Buy	535,772 +75	+0%	+$2.22K	﹤0.01%	1747
2019 Q2	$16.1M	Buy	535,697 +68,863	+15%	+$1.58M	﹤0.01%	1713
2019 Q1	$10.5M	Buy	466,834 +53,445	+13%	+$1.15M	﹤0.01%	1848
2018 Q4	$7.52M	Buy	413,389 +338,801	+454%	+$5.32M	﹤0.01%	1894
2018 Q3	$1.35M	Sell	74,588 -6,500	-8%	-$77K	﹤0.01%	2438
2018 Q2	$807K	Buy	+81,088	New	+$560K	﹤0.01%	2458

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments's RARX Position: Q4 2019 in Review

Fidelity Investments sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 535,772 shares — an estimated $12.7M sold.

Fidelity Investments first reported a position in RARX in Q2 2018 and held it in 6 quarters. The position peaked at $16.1M in Q2 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

Fidelity Investments reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Fidelity Investments sold 535,772 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $12.7M.
Fidelity Investments first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 6 quarters.
Fidelity Investments's Ra Pharmaceuticals, Inc. Common Stock position peaked at $16.1M in Q2 2019.
146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Fidelity Investments's 13F filing for Q4 2019, filed 7 Feb 2020.